ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
FDA Removes Amputation Boxed Warning for Canagliflozin
August 28, 2020Based on a U.S. Food and Drug Administration (FDA) review of new data from three clinical trials, the FDA has removed the Boxed Warning about amputation risk from the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR) prescribing ... -
Canagliflozin may not be associated with fracture risk in diabetes patients
January 03, 2019A study has found that when compared with other drugs, canagliflozin may not be associated with fractures in patients with diabetes… -
J&J's Invokana becomes first FDA-approved oral diabetes drug to reduce cardiovascular event risk
November 01, 2018The FDA has given the go-ahead for Johnson & Johnson’s drug Invokana (canagliflozin) for use in the risk reduction of major adverse cardiovascular (CV) events, making it the “first and only oral diabetes treatment.....
Pharma Sources Insight January 2025
